ÂÜÀòÂÒÂ×

Craig Beeson is a co-founder at MitoChem Therapeutics. Craig was previously with MitoHealth and the Medical University of South Carolina. Prior to that, they were a postdoctoral associate at Stanford University from January 1993 to December 1996, where they researched biophysics and T-cell immunology.

Craig Beeson has a PhD in organic chemistry from UC Irvine and did a postdoc in Chemistry and Immunology at Stanford University School of Medicine.

Some of their coworkers include Bärbel Rohrer - Co-Founder & CSO. Craig Beeson reports to Michael Voevodsky, President & CEO.